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Summary Serum levels of cell-free interleukin-2 receptors were elevated above normal in mice bearing the
IL-2R positive T-cell lymphoma Eb or its highly metastatic variant ESb. Although ESb cells expressed less
IL-2R molecules than Eb cells on their cell surface, serum receptor levels were raised more quickly in ESb
than in Eb tumour bearing animals. Elevated IL-2R serum levels were a sensitive tumour marker in animals
bearing the aggressive variant ESb but not in animals bearing the low metastatic line Eb. Peritoneal ascites
tumour-bearing animals had higher serum IL-2R levels than corresponding animals with subcutaneously
growing tumours. Thus, serum IL-2R levels in tumour-bearing animals were dependent on the tumour line
and influenced by the site and mode of tumour growth.
It has been shown that the growth factor interleukin 2 (IL-2)
and its receptor (IL-2R) (Robb et al., 1981) are absent in
resting T-cells. Most resting T-cells, B-cells or macrophages
in the circulation do not display IL-2 receptors (Waldmann,
1986). Thus less than 5% of freshly isolated unstimulated
human peripheral blood T-lymphocytes react with the mono-
clonal antibody to the IL-2 receptor anti-Tac (Uchiyama et
al., 1981). Most T-lymphocytes, however, can be induced to
express IL-2 receptors after stimulation of their T-cell
antigen receptor complex by antigens or by stimulation of
the cells with monoclonal antibodies or with mitogenic
lectins (Diamantstein & Osawa, 1986; Shimizu et al., 1986).
After activation, the genes for both proteins, IL-2 and IL-2R
become expressed (Waldmann, 1986; Malek et al., 1986).
In contrast to resting T-cells, human T-cell lymphotrophic
virus I (HTLV-I)-associated adult T-cell leukaemia cells
constitutively express large numbers of IL-2 receptors (Yodoi
et al., 1983; Yodoi & Uchiyama, 1986; Waldmann et al.,
1984). Because IL-2 receptors are present on the malignant
T-cells but not on normal resting cells, clinical trials have
been initiated in which patients with adult T-cell leukaemia
are treated with the monoclonal antibody that binds to the
IL-2 receptor.
Such studies may be complicated, however, by the
modulation and shedding of IL-2 receptor material
(Waldmann, 1986). Rubin et al. (1985) demonstrated that
activated normal peripheral blood mononuclear cells and
certain lines of T- and B-cell origin release a soluble form of
the IL-2 receptors into the culture medium. Normal
individuals were found to contain measurable amounts of
IL-2 receptors in their plasma and certain lymphoreticular
malignancies were found to be associated with elevated
plasma levels of this receptor. It is obvious that this material
could compete not only for binding of IL-2 but also for anti
receptor antibody.
In certain conditions the determination of serum or
plasma levels of soluble IL-2R might be a useful additional
diagnostic marker. In the present study we have therefore
compared the serum levels of IL-2R in normal animals or in
animals which had been inoculated with IL-2 receptor
positive well defined tumour lines (Diamantstein et al.,
1985). The tumour lines used were various sublines from the
chemically induced T-cell lymphoma L5178YE of DBA/2
mouse origin which differed greatly in their overall meta-
static capacity (Schirrmacher et al., 1979a). The parental line
Eb is of low metastatic capacity when inoculated subcutan-
Correspondence: V. Schirrmacher.
Received 20 October 1986; and in revised form 20 January 1987.
eously while the spontaneous in vivo variant ESb is.of high
metastatic capacity in the spontaneous metastasis assay
(Schirrmacher et al., 1982). A plastic adherent variant,
ESb-M, was isolated in tissue culture from the high meta-
static line ESb and was shown to have greatly decreased
metastatic capacity in vivo (Fogel et al., 1983). The Eb and
ESb cell lines have been characterized previously as being
IL-2 receptor positive (Diamantstein et al., 1985). The cells
do not produce IL-2 constitutively nor could they be
stimulated to secrete IL-2. These results thus did not support
the autocrine stimulation hypothesis. Furthermore, the low
metastatic parental line Eb was found to express more IL-2
receptors as detected both by binding of the monoclonal anti
IL-2R antibody AMT-13 (Osawa & Diamantstein, 1984a,b)
and by absorption of IL-2 activity. Here we will demonstrate
that soluble IL-2R can be detected in the serum of normal
and tumour bearing animals when using a sensitive enzyme-
linked immunosorbent assay with two monoclonal antibodies
that recognize distinct epitopes on the mouse IL-2 receptor.
We will describe quantitative differences between tumour
bearer and normal serum levels and studies on the dose
dependence and kinetics of the appearance of elevated IL-2R
in tumour bearing animals. Finally we will describe and dis-
cuss differences observed with cell lines of high and low
metastatic capacity.
Materials and methods
Tumour cell lines
The origin and aetiology of the three tumour lines Eb, ESb
and ESb-M have been described previously (Schirrmacher
et al., 1982; Fogel et al., 1983). Their in vivo growth charac-
teristics and metastatic spread have also been described
previously (Schirrmacher et al., 1979a, 1982; Fogel et al.,
1983). The spontaneous high metastatic variant ESb is most
likely derived from a spontaneous fusion of the parental T-
lymphoma Eb with a host macrophage (Larizza et al., 1984).
The two lines were found to differ in many cell surface
properties including expression of differentiation antigens
(Altevogt et al., 1982), of composition of membrane glyco-
proteins (Schwartz et al., 1984), glycolipids (Murayama et
al., 1986) and in the shedding of membrane vesicles (Barz et
al., 1985; Schirrmacher & Barz, 1986). The plastic adherent
ESb-MP line which is derived from ESb-M was found to be
more similar to ESb cells in its cell surface phenotype and
also in functional properties in vitro such as invasiveness in
organ coculture systems (Waller et al., 1986). In vivo,
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however, the ESb-M line showed greatly decreased overall
malignancy (Benke et al., 1987).
ELISA-assayfor determination ofsoluble IL-2R
IL-2R were determined according to Osawa et al. (1986a) as
modified by Osawa et al. (1986b). Wells of round-bottomed
96-well polystyrol microtiter plates (Greiner, Niirtingen,
FRG) were incubated at 4°C overnight with 0.1 ml
(6pgml-1) of purified 7D4 (Malek et al., 1983) in PBS
containing 0.02% NaN3 (PBS/NaN3). The antibody solution
was removed and the plates were then incubated at 37°C for
1 h with PBS/NaN3 containing 3% bovine serum albumin
(BSA) and consequently washed twice with PBS containing
0.1% Tween-20 (PBS/Tween). To the wells were added
0.1 ml of two-fold serial dilutions of the samples containing
the probes. Sample dilutions were performed by using the
lysis buffer. The probes were incubated for 1 h at 37°C. They
were then washed with PBS/Tween three times and allowed
to react with 0.1 ml (0.5-1 Mgml-1) of biotinylated AMT-13
(Osawa & Diamantstein, 1984a) in PBS/NaN3 containing
1% BSA for I h at 37°C, followed by washes with
PBS/Tween. Biotinylated AMT-13 bound to the wells was
detected by incubation for 1 h at 37°C with 0.1 ml of a
1/1000 dilution of streptavidin peroxidase complex
(Amersham-Buchler, Braunschweig, FRG) in PBS containing
1% BSA, followed by washes with PBS/Tween and
incubation at 37°C with 0.1 ml of peroxidase substrates
containing 0.55mg of 2,2-azino-bis-(3-ethylbenzthiaziline
sulfonic acid) (ABTS; Sigma Chemie) in 0.1 M citrate/phos-
phate buffer (pH5.3). After 30min the reaction was stopped
by the addition of 50#l 0.1 M citric acid containing 0.01%
NaN3. The absorbance of the wells was determined at
405 nm by a Titertel ELISA reader (Flow Laboratories
GmbH, Meckenheim, FRG).
Results
IL-2 receptor levels in the serum ofnormal or tumour bearing
animals
In Table I we have summarized serum levels of cell-free IL-2
receptors as determined by a sensitive ELISA-assay involving
two monoclonal antibodies reactive with different epitopes of
the mouse IL-2 receptor. Normal IL-2R levels (Table I;
control group I) were in the range of 10 to 30 ngml-1 while
some animals had levels below the threshold of detection
(O0ngml-1). In Table I, group II, we have-listed the serum
IL-2R levels of animals bearing the highly metastatic IL-2R
positive tumour ESb. Seven of the 10 animals had levels
> 100 ngml- 1 and only one serum had an undetectable level.
We have also listed the numbers of macroscopically visible
liver metastases. Six of the 10 animals had liver metastases
and all of these had significantly elevated serum IL-2R
levels. Three of the 4 liver metastasis negative animals also
had elevated IL-2R levels in their serum. In group III we
have listed the receptor levels determined in animals which
had been inoculated with the plastic adhesive variant ESb-
MP. The experimental conditions (tumour dose (106), route
of inoculation (i.p.), time of serum removal) were identical in
the experimental groups II-IV. The receptor levels of all
ESb-MP tumour bearing animals were <50 ng ml-. In
contrast, animals bearing the IL-2R positive parental tumour
Eb showed serum levels >50ngml-'. Three of 10 animals
had levels > O00 ngml -1.
All tumour bearing groups had significantly elevated IL-2
receptor serum levels (for P values, see Table I). It is
interesting that animals bearing the highly metastatic tumour
ESb had significantly higher IL-2R levels than those with
ESb-MP and even those with the parental tumour Eb,
although Eb cells were more strongly IL-2R positive than
ESb cells (Diamantstein et al., 1985) (for P values, see
Table I).
Tumour dose dependency of serum IL-2 receptor levels
Next we investigated the appearance of increased levels of
serum IL-2R in animals which had been inoculated with
decreasing amounts of either Eb or ESb tumour cells. In
Figure 1 we have illustrated the individual values obtained
from animals (i) before tumour inoculation (normal serum
values) or from animals one week (1 wk) or 2 weeks (2wk)
after i.p. inoculation of either 106, 105 or 104 tumour cells.
The majority of normal serum levels (12 from 14) were
<30ngml-1. Similar levels were seen in animals inoculated
Table I IL-2R level in the serum of normal or tumour-bearing animals: comparison
of IL-2R positive tumours with high or low metastatic capacity
Animal Liver IL-2Ra Animal Liver IL-2Ra
Group no. metastases ngml- no. metastases ngml 1
I Control 1 12 6 - 20
2 - .10 7 - <10
3 - 15 8 - 30
4 - .10 9 - 15
5 - .10 10 - 15
II ESb 1 8 150 6 3 105
106 i.p. 2 - 110 7 - 70
3 - <10 8 9 68
4 4 210 9 1 1 215
5 - 160 10 2 160
III ESb-MP 1 - 30 6 - 32
106i.p. 2 - 15 7 - 12
3 - 20 8 - 15
4 - 28 9 - 15
5 - 42 10 - 20
IV Eb 1 - 92 6 - 55
106 i.p. 2 - 65 7 - 95
3 - 110 8 - 100
4 - 50 9 - 75
5 - 135 10 - 97
aDetermined in the serum of tumour-bearing animals 8 days after tumour
inoculation. Values from experimental groups are significantly different from those of
the control group. P values (Wilcox 2) were as follows: II 0.0007; III 0.0232, IV
<0.0001. Values of group II were significantly higher (P=0.0008) than those of
group III and significantly higher (P =0.0446) than those of group IV.SERUM IL-2 RECEPTOR LEVELS OF TUMOUR ANIMALS 585
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Figure 1 Tumour dose dependency of serum IL-2R levels in
tumour-bearing animals. Groups of DBA/2 mice were inoculated
i.p. with 106, 105 or 104 cells of either low metastatic Eb (A) or
of high metastatic ESb (0) cells and individual serum IL-2R
levels determined after 1 or 2 weeks. The values of ESb tumour
bearing animals (ESb I WK i.p. 105 and 106) were significantly
higher than the normal serum values of Figure 1 and Table I
(P<0.00001; Wilcox 2).
with 104 tumour cells and tested one week later. In contrast,
animals inoculated with 105 or 106 ESb tumour cells all
showed significantly higher IL-2R levels as early as one week
after inoculation. At 2 weeks after inoculation of ESb
tumour cells most animals were dead while those which
survived had also elevated serum levels. In Eb tumour
bearing animals serum receptor levels were highly elevated
when tested after 2 weeks (values between 70 and
700ngml- 1). After one week only some of the animals
inoculated with 106 or 105 Eb tumour cells had serum IL-2R
levels >30ngml -1.
These results thus corroborate the data in Table I. A rise
in serum IL-2R level was more prominent in animals bearing
the highly metastatic tumour than in those bearing the low
Next we compared the kinetics of the rise of IL-2R levels in
the serum of animals bearing subcutaneous tumours. The
results of a comparison between Eb and ESb tumour bearing
animals are shown in Figure 2. Individual animals were bled
only once in order not to disturb the receptor level in the
blood. Each time point therefore represents a different group
of animals. We have also illustrated in the figure the
development of the local tumour growth in terms of mean
tumour diameter. Animals bearing ESb tumour cells only
developed small local tumours before they died after 11 to
12 days, while those bearing Eb tumours developed larger
tumours with a diameter >2cm. Elevated IL-2R levels were
detected in all ESb tumour bearing animals shortly before
their death and in the majority of animals as early as 4 days
after s.c. tumour inoculation. In Eb tumour bearing animals
the kinetics of elevation of serum IL-2 receptor levels was
much slower and elevated levels were not detected in all
animals per group even when tested in the late phases of
tumour growth. This can be seen best with the values
obtained 35 days after tumour inoculation where 3 animals
had very high levels (> 1,000ngml 1-), while 3 other animals
had levels <50ngml-1. If we compare serum IL-2R levels
in animals with tumour cells growing s.c. (Figure 2) with
those of animals with tumours growing i.p. (Figure 1) it
seems that in the latter group shedding of cell-free IL-2R is
more regularly detectable in the serum than in the former
group. In Eb tumour bearing animals, the difference in
serum IL-2R level between i.p. or s.c. tumour growth was
statistically significant (P<0.0001). The biological and/or the
anatomical conditions of the site where the tumour is
growing might thus influence the release or degradation of
IL-2 receptors by tumour cells.
Discussion
In a previous report we have described our studies on
interleukin 2 receptor expression and IL-2 production by
murine T-cell lymphomas (Diamantstein et al., 1985). Here
we have used two sublines of an IL-2R positive T-cell
lymphoma which differ greatly in metastatic capacity and
compared the level of cell-free IL-2R in tumour bearing
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Figure 2 Kinetics of rise of serum IL-2R levels in animals inoculated s.c. with Eb (A) or ESb (0) tumour cells. Each point
represents the value from a separate individual animal. The values obtained from Eb s.c. inoculated animals (e.g. at day 14) were
significantly lower than the corresponding values after i.p. inoculation of Eb cells (see Figure 1) P<0.0001 (Wilcox 2).
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animals under different conditions of tumour growth. These
studies were initiated in order (i) to determine whether
soluble IL-2 receptors in the serum of IL-2 receptor positive
tumour bearing animals might be a sensitive tumour marker
and (ii) to see whether such a marker might correlate with
the extent of metastasis and tumour progression. The com-
parison of high and low metastatic related tumour lines also
aimed at the question whether metastatic cells might shed
more receptor material than non-metastatic cells, a
phenomenon which has been observed before in the same
tumour system when analyzing release of Fc receptors
(Schirrmacher & Jacobs, 1979) and release of membrane
vesicles (Barz et al., 1985; Schirrmacher & Barz, 1986) in
tumour-bearing animals.
The tumour lines used in this study have previously been
shown to express IL-2 receptors although to a different
extent (Diamantstein et al., 1985). The low metastatic Eb
cells bound high levels of AMT 13 antibody while the high
metastatic ESb variant cells bound less but still significant
amounts of AMT 13 antibody. The ESb derived plastic
adhesive variant ESb-MP which has a greatly reduced meta-
static capacity (Benke et al., submitted) also expressed small
but significant amounts of IL-2 receptor. The differences in the
capacity of these related sublines to bind AMT 13 antibody
were revealed with the help of a fluorescence activated cell
sorter by determining the level of positive cells as well as the
mean fluorescence intensity. On the basis of these results it is
especially interesting to note that animals bearing the highly
metastatic tumour line ESb showed the highest levels of cell-
free IL-2R in their serum (Table I). Under comparable
conditions, animals inoculated with the parental line Eb or
with the plastic adhesive variant ESb-MP showed IL-2R
levels in the serum which were either similar to or slightly
above the levels found in normal animals. The level of
soluble IL-2R reflects the rate of release per tumour cell, the
body burden of tumour cells and the fractional rate of
catabolism of the receptor. In case of the ESb-MP cells the
low IL-2R levels could be influenced by a reduced growth
capacity in vivo (Benke et al., submitted) but this explanation
does not hold true for the parental line Eb because animals
inoculated with Eb or ESb tumour cells i.p. develop ascitic
tumours which contain similar amounts of tumour cells. In
case of the ESb variant with its high metastatic potential, the
high IL-2R levels could be influenced by the fact the cells of
the tumour are more widely distributed in the body. Another
reason could be an increased release of IL-2R on a per cell
basis when compared with the two related low metastatic
lines.
The analysis in Table I also served to investigate the
relationship between IL-2R level in the serum and the status
of metastasis. Six of the 10 animals had macroscopically
visible liver metastases and all of these had elevated serum
receptor levels. From the 4 negative animals of group II, 3
also had elevated serum IL-2R levels. Thus in these animals
the IL-2R serum marker indicated the presence of tumorous
growth although there were no macroscopically visible
metastases. These animals could have had micrometastases
below the level of macroscopic detection or tumour growth
in the peritoneum without dissemination to internal organs.
These data suggest that cell-free IL-2R levels in the serum
might be a useful diagnostic and prognostic marker for IL-
2R positive tumours with good receptor shedding capacity.
The experiments on the tumour dose dependency (Figure
1) and on the kinetics of elevated serum IL-2R expression
further corroborated the differences seen before between
animals bearing the high metastatic ESb cells as compared to
the parental low metastatic cell line Eb. One week after ESb
transfer animals inoculated i.p. (Figure 1) or s.c. (Figure 2)
showed on the average higher values than corresponding
animals inoculated with the Eb tumour line. Significant
differences were seen between the values obtained from Eb
tumour bearing animals inoculated either i.p. or s.c., the
former being higher than the latter.
We have thus shown that the serum of animals bearing
IL-2 receptor positive tumours can show levels of cell free
IL-2R which are significantly above those of normal control
animals. It is likely that these increased receptor levels are
due to release of the receptors from the tumour cells because
the level of receptor in the serum correlates with the tumour
status: They increase with time of tumour growth and with
the dose of tumour cells inoculated. It cannot be excluded,
however that some of the serum IL-2R may be derived from
host cells responding to and being activated by the growing
tumour cells. We have demonstrated previously that both Eb
and ESb tumour cells can activate tumour specific T-cell
mediated immune responses detectable as tumour specific
cytotoxic T-lymphocytes (Schirrmacher et al., 1979b). There
are no serological reagents available so far that could
distinguish tumour derived IL-2R from those of normal cells
so that the relative contribution of both to the actual serum
IL-2R level cannot be accurately determined.
Perhaps the most remarkable finding of this analysis is the
increased speed of appearance of elevated serum IL-2R levels
by metastatic as compared to non-metastatic tumour cells.
We have shown before that ESb cells shed more Fc receptors
into the serum than Eb cells (Schirrmacher & Jacobs, 1979)
and that the release is mediated via the shedding of extra-
cellular plasma membrane vesicles (Schirrmacher & Barz,
1986). ESb cells shed about three times as many vesicles than
Eb cells and these vesicles differ in their chemical and
biochemical composition from the original plasma
membranes (Barz et al., 1985). It was therefore concluded
that the process of plasma membrane exfoliation represents a
selective rather than a random process. It results in the
selective release of certain membrane molecules including
certain receptors, tumour antigens (Schirrmacher & Barz,
1986) and degradative enzymes (Kramer et al., 1985). An
increased release of IL-2 growth factor receptor by meta-
static tumour cells could have a selective growth advantage
for the tumour cells because these receptors might absorb
the growth factor IL-2 which is required for growth and
expansion of host T-lymphocytes with anti-tumour activity.
Since the tumour cells themselves are independent in their
growth from external IL-2, as shown previously
(Diamantstein et al., 1985) this secretion of IL-2 absorbing
molecules from the cell surface might interfere with the host
response against the tumour and could thus have a selective
advantage for the growing tumour cells. The suppression of
T-cell responses through competition for T-cell growth factor
(IL-2) has been described before (Gunther et al., 1982). A
selective suppression of cell-mediated autoimmunity has been
observed following treatment with anti-IL-2R monoclonal
antibodies (Diamantstein & Osawa, 1986).
Further experiments are necessary to elucidate in vitro the
release of IL-2R by Eb, ESb and ESb-MP cells. It will be of
interest to determine whether the released receptor material
is membrane bound or whether it is derived perhaps by
direct secretion of a variant of the IL-2R which does not
bear the transmembrane hydrophobic region that is
produced by an independent mRNA lacking this exon of the
IL-2 receptor.
The most common human tumour expressing IL-2
receptor is adult T-cell leukaemia (ATL) (Yodoi &
Uchiyama, 1986; Waldmann et al., 1984; Yodoi et al., 1983).
It will be interesting to study cell-free IL-2R levels in the
serum of ATL patients to see whether this might be a useful
additional diagnostic and prognostic marker in this disease.
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